JP2016506413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506413A5 JP2016506413A5 JP2015551113A JP2015551113A JP2016506413A5 JP 2016506413 A5 JP2016506413 A5 JP 2016506413A5 JP 2015551113 A JP2015551113 A JP 2015551113A JP 2015551113 A JP2015551113 A JP 2015551113A JP 2016506413 A5 JP2016506413 A5 JP 2016506413A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- tumor
- recombinant interferon
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- 102000014150 Interferons Human genes 0.000 claims 12
- 108010050904 Interferons Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229940079322 interferon Drugs 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 238000007910 systemic administration Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- 238000010317 ablation therapy Methods 0.000 claims 1
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749570P | 2013-01-07 | 2013-01-07 | |
| US61/749,570 | 2013-01-07 | ||
| US201361779711P | 2013-03-13 | 2013-03-13 | |
| US61/779,711 | 2013-03-13 | ||
| PCT/CN2014/000019 WO2014106459A2 (en) | 2013-01-07 | 2014-01-07 | A method for treating tumor by using recombinant interferon with changed spatial configuration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190263A Division JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506413A JP2016506413A (ja) | 2016-03-03 |
| JP2016506413A5 true JP2016506413A5 (enExample) | 2017-02-16 |
Family
ID=51062515
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Pending JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2015551113A Pending JP2016506413A (ja) | 2013-01-07 | 2014-01-07 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2020066723A Pending JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Pending JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2020066723A Pending JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20160022778A1 (enExample) |
| EP (3) | EP2941266B1 (enExample) |
| JP (5) | JP2016508987A (enExample) |
| KR (4) | KR20210069127A (enExample) |
| CN (2) | CN104902917A (enExample) |
| AU (2) | AU2014204386B2 (enExample) |
| CA (2) | CA2897335A1 (enExample) |
| HK (2) | HK1216394A1 (enExample) |
| TW (3) | TWI718086B (enExample) |
| WO (2) | WO2014106459A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| CN107847564B (zh) * | 2015-05-12 | 2021-11-09 | 远东超级实验室有限公司 | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN108721603B (zh) * | 2017-04-14 | 2020-11-13 | 中国医学科学院基础医学研究所 | 干扰素α-1a在制备用于治疗癌症的药物中的用途 |
| KR101880015B1 (ko) * | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
| WO2020112991A1 (en) * | 2018-11-27 | 2020-06-04 | The Children's Hospital Of Philadelphia | Compositions and methods for treating cancer |
| US20220251605A1 (en) * | 2019-06-14 | 2022-08-11 | The Brigham And Women's Hospital, Inc. | Membrane attack complexes and uses thereof |
| CN111658779A (zh) * | 2020-06-22 | 2020-09-15 | 四川大学华西医院 | 治疗新型冠状病毒肺炎的联合用药物 |
| WO2022156735A1 (zh) * | 2021-01-21 | 2022-07-28 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的癌症治疗方法和药物组合 |
| US11759434B2 (en) * | 2022-02-03 | 2023-09-19 | Sytheon Limited | Methods and compositions for treating melanoma and non-melanoma skin cancers |
| CN114533706B (zh) * | 2022-02-15 | 2022-10-14 | 深圳市利云德生物技术有限公司 | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 |
| WO2024076973A1 (en) * | 2022-10-04 | 2024-04-11 | Brown University | Compositions and methods of delivering large proteins |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005169A (en) * | 1932-08-27 | 1935-06-18 | Rowe Andrew Reed | Casting metal ingots |
| US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4681930A (en) | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
| PL172758B1 (pl) | 1992-10-19 | 1997-11-28 | Dura Pharma Inc | Inhalator do proszków suchych PL PL PL PL PL PL PL |
| AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
| US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| WO1995017901A1 (en) * | 1993-12-29 | 1995-07-06 | Matrix Pharmaceutical, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| EP0861321B1 (en) | 1995-10-13 | 2006-05-31 | President And Fellows Of Harvard College | Phosphopantetheinyl transferases and uses thereof |
| GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| US6065472A (en) | 1996-01-03 | 2000-05-23 | Glaxo Wellcome Inc. | Multidose powder inhalation device |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
| CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
| US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
| JP3983985B2 (ja) * | 2000-03-22 | 2007-09-26 | 株式会社東芝 | ＭｘＡタンパク質の多型遺伝子およびその使用 |
| IL155741A0 (en) | 2000-11-03 | 2003-12-23 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| US8551469B2 (en) * | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
| US8158145B2 (en) | 2002-02-19 | 2012-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous absorption type plaster |
| WO2004091571A2 (en) | 2003-04-08 | 2004-10-28 | New Jersey Institute Of Technology (Njit) | Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| MY141751A (en) * | 2003-08-28 | 2010-06-30 | Sichuan Biotechnology Res Ct | Recombinant super-compound interferon |
| US7585647B2 (en) * | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| ES2473622T3 (es) * | 2003-08-28 | 2014-07-07 | Superlab Far East Limited | Usos de interferones con estructura espacial alterada |
| WO2005021777A2 (en) | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
| CN1910195A (zh) * | 2003-08-28 | 2007-02-07 | 辉阳科技美国公司 | 通过空间构象调节蛋白质功能 |
| FR2862541B1 (fr) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques |
| WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| US20080102114A1 (en) * | 2004-04-23 | 2008-05-01 | Panduranga Rao Koritala | Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents |
| CN1740197B (zh) | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
| EP1868636A4 (en) * | 2005-03-09 | 2012-03-28 | Guangwen Wei | USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| WO2006133088A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US8071125B2 (en) | 2005-12-09 | 2011-12-06 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Transdermal patch containing isosorbide dinitrate and bisoprolol |
| EP2056883B1 (en) | 2006-08-04 | 2021-09-22 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US8095213B1 (en) | 2007-05-31 | 2012-01-10 | Purdue Pharma L.P. | Transdermal patch |
| ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| EP2413901A4 (en) * | 2009-03-30 | 2015-05-06 | Cerulean Pharma Inc | POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES |
| EP2239580B1 (en) | 2009-04-09 | 2013-03-27 | Lga Biotecnologie Srl | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis |
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| CA2812644A1 (en) | 2010-09-27 | 2012-04-05 | Zestagen, S.A. | Compositions and methods for treating neoplasia |
| US9107887B2 (en) * | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| US20130184437A9 (en) | 2011-06-08 | 2013-07-18 | Guangwen Wei | Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| US20130273527A1 (en) * | 2012-04-13 | 2013-10-17 | Superlab Far East Limited | Method for inducing cell senescence by recombinant interferon with altered spatial configuration |
| AU2013293049A1 (en) * | 2012-07-20 | 2015-02-26 | La Trobe University | Method of diagnosis and treatment |
| TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| KR102230547B1 (ko) | 2013-11-13 | 2021-03-22 | 수퍼랩 파 이스트 리미티드 | 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도 |
-
2014
- 2014-01-06 TW TW103100472A patent/TWI718086B/zh not_active IP Right Cessation
- 2014-01-06 TW TW103100470A patent/TW201427681A/zh unknown
- 2014-01-06 TW TW108107884A patent/TWI726291B/zh active
- 2014-01-07 HK HK16104396.4A patent/HK1216394A1/zh unknown
- 2014-01-07 KR KR1020217016953A patent/KR20210069127A/ko not_active Ceased
- 2014-01-07 CN CN201480003935.3A patent/CN104902917A/zh active Pending
- 2014-01-07 KR KR1020157021423A patent/KR20150139824A/ko not_active Ceased
- 2014-01-07 US US14/759,410 patent/US20160022778A1/en not_active Abandoned
- 2014-01-07 WO PCT/CN2014/000019 patent/WO2014106459A2/en not_active Ceased
- 2014-01-07 EP EP14735273.6A patent/EP2941266B1/en active Active
- 2014-01-07 KR KR1020157021350A patent/KR20150103284A/ko not_active Ceased
- 2014-01-07 CA CA2897335A patent/CA2897335A1/en not_active Abandoned
- 2014-01-07 US US14/759,483 patent/US20150352188A1/en not_active Abandoned
- 2014-01-07 HK HK16102577.9A patent/HK1214528A1/zh unknown
- 2014-01-07 AU AU2014204386A patent/AU2014204386B2/en active Active
- 2014-01-07 CN CN201480003898.6A patent/CN104994866A/zh active Pending
- 2014-01-07 CA CA2897312A patent/CA2897312C/en active Active
- 2014-01-07 JP JP2015551117A patent/JP2016508987A/ja active Pending
- 2014-01-07 JP JP2015551113A patent/JP2016506413A/ja active Pending
- 2014-01-07 EP EP14735427.8A patent/EP2941264B1/en active Active
- 2014-01-07 WO PCT/CN2014/070212 patent/WO2014106492A2/en not_active Ceased
- 2014-01-07 KR KR1020217018383A patent/KR20210077005A/ko not_active Ceased
- 2014-01-07 AU AU2014204368A patent/AU2014204368B2/en active Active
- 2014-01-07 EP EP21161499.5A patent/EP3895725A3/en active Pending
-
2018
- 2018-07-18 US US16/038,704 patent/US20180326012A1/en not_active Abandoned
- 2018-07-25 US US16/044,582 patent/US10874716B2/en active Active
-
2019
- 2019-10-17 JP JP2019190263A patent/JP2020023547A/ja active Pending
-
2020
- 2020-04-02 JP JP2020066723A patent/JP2020105223A/ja active Pending
- 2020-12-29 US US17/136,656 patent/US12109250B2/en active Active
-
2021
- 2021-12-09 JP JP2021200049A patent/JP2022031331A/ja active Pending
- 2021-12-13 US US17/548,598 patent/US20220339255A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506413A5 (enExample) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| Yao et al. | Cytokine regulation of metastasis and tumorigenicity | |
| Apetoh et al. | Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? | |
| Zhang et al. | Drug delivery system targeting advanced hepatocellular carcinoma: Current and future | |
| JP2016538344A5 (enExample) | ||
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2018503668A5 (enExample) | ||
| JP2015505843A5 (enExample) | ||
| Wall et al. | Targeting tumors with salmonella Typhimurium-potential for therapy | |
| JP2019506862A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| CN111344398A (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| JP2018521135A5 (enExample) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| NZ726365A (en) | Combinations for treating cancers | |
| JP2011157399A5 (enExample) | ||
| AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
| HK1232242A1 (zh) | 用於癌症靶向治疗的包含基於重组血红蛋白蛋白质或亚基的治疗剂的药物组合物 | |
| JP2019506392A5 (enExample) | ||
| JP2015514115A5 (enExample) | ||
| JP2015518835A5 (enExample) | ||
| JP2016533373A5 (enExample) | ||
| JP2018509423A5 (enExample) | ||
| WO2006004620A3 (en) | Enterotoxin gene cluster (egc) superantigens to treat malignant disease |